Skip to content

News

Rucaparib Receives Breakthrough Therapy Designation from FDA

Rucaparib Receives Breakthrough Therapy Designation from FDA

(April 14, 2015) The FDA granted breakthrough therapy designation to rucaparib as monotherapy for patients with advanced ovarian cancer. Rucaparib is an oral, small-molecule PARP inhibitor developed for the treatment … Continued

Microenvironment Regulates Tumor Suppressor miRNA

Microenvironment Regulates Tumor Suppressor miRNA

(April 2, 2015) According to a study published in the journal Oncogene, the tumor microenvironment can regulate tumor suppressor miRNA in ovarian cancer cells. The direct interaction of the ovarian … Continued

New Tool Could Speed Development of Ovarian Cancer Drugs

New Tool Could Speed Development of Ovarian Cancer Drugs

(February 13, 2015) University of Chicago Medicine researchers, including OCRF grantee and Scientific Advisory Committee member Ernst Lengyel, MD, PhD, have built a model system that uses multiple cell types … Continued

Meet OCRF’s 2015 Grantees

Meet OCRF’s 2015 Grantees

(February 11, 2015) Ovarian Cancer Research Fund has announced that $6.1 million has been awarded in scientific research grants for ovarian cancer. This brings OCRF’s total investment in research and related educational … Continued

SGI-110 is an Ovarian Cancer Chemosensitizer

SGI-110 is an Ovarian Cancer Chemosensitizer

(February 4, 2014)  In research published last October in Clinical Cancer Research, a team of OCRF-funded investigators showed that a novel therapy can resentisize ovarian cancer to chemotherapy.  The work … Continued

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

We care about your data. Read our privacy policy.